TUMI 'Packs' A Punch With New York City-Inspired Fall 2025 Collection
New York City is TUMI's design nucleus, and the Fall 2025 collections celebrate the movers, makers and creative spirits that drive the heartbeat of the concrete jungle with creations that are as multifaceted and resilient as the city itself.
An exploration of New York City's constant evolution, the Fall 2025 collections feature prints that pay homage to the iconic wild postings scattered across the city's streets and neighbourhoods. Select pieces from the Alpha, Alpha Bravo and Voyageur collections are imagined in a poster print, featuring a torn poster graphic that alludes to the history underpinning all the innovations to come.
The Alpha Bravo collection, known for its high-performance 'go-anywhere' silhouettes, finds a fresh feel with a new core colourway: Navy Coated Canvas, an elevated alternative to classic black, perfect for every day. Fall 2025 includes seasonal hues, Pavement and Electric Blue, both inspired by the architecture of the metropolis. New commuter-ready styles—the Surveillance Flap Backpack and Roadstead Messenger—round out the collection.
This season, men's styles receive an exciting refresh with the premium, automotive-inspired Arrivé collection, introducing new details like carbon fibre accents and quiet, magnetic zipper garages. The relaunch spotlights the Arrivé Large Backpack, refined with modern accents and considered upgrades that elevate both function and finish—bringing renewed energy to one of TUMI's most sophisticated silhouettes.
Complementing the lineup, the Arrivé Hannover Slim Brief offers a sleek, minimalist option for streamlined business travel, crafted with the same precision and polish. Expanding the Harrison collection, new styles include the Griffen Flap Backpack, adding further variety. Under Fall 2025, Harrison also ushers in Burnished Wine Ombre, a gradient technique that gives its whole-grain leather a distinctive, textured appearance.
Inspired by the city's bold graffiti murals, the brand's bestselling Just In Case® styles feature a dripped spray paint design (and, new for Fall 2025, three diverse sizes of the signature tote silhouette). Folding completely flat, Just In Case® is the perfect addition to every traveller's lineup.
This season also introduces new colourways across core Voyageur styles—including the Celina Backpack—with Deep Olive, Mink, Moonlight, and Blackberry offering elevated versatility for life on the move.
Designed with versatility and sophistication in mind, the Olas and Agent collections expand TUMI's offering for the modern woman. Olas embraces a minimalist sensibility with clean lines and soft structure, available in essential silhouettes like the Small and Medium Shoulder Bags.
Agent, crafted in lightweight leather and finished with refined hardware, offers a seamless blend of fashion and function—from boardroom to off-duty moments—ensuring every detail is thoughtfully considered.
The iconic 19 Degree collection returns with seasonal colourways inspired by the atmospheric elegance of Central Park in the Fall. 19 Degree Lite introduces rich, grounded tones of wine and pavement—each echoing the foliage, stone paths and surrounding brownstones of the park's storied landscape.
Moonrock appears in 19 Degree Polycarbonate, extending the palette's quiet sophistication across the broader collection.
New to 19 Degree Aluminium comes an unexpected and opulent object for those with discerning taste: the 19 Degree Aluminium Bar Set. This luxurious bar set includes every glass and accessory needed to craft the perfect cocktail, including exclusive TUMI cocktail recipe cards.
Exquisitely packaged in a premium aluminium case featuring the brand's iconic 19 Degree contours, the new bar set is the perfect pinnacle lifestyle piece for TUMI enthusiasts.
Rounding out TUMI's 50th anniversary year are select travel and lifestyle pieces and accessories featuring the brand's signature TUMI Red Pantone artfully deployed as both a pop of colour accent and as an allover treatment.
Together, the Fall 2025 collections are the perfect forward-looking way to celebrate 50 years of innovation —all expressed through the graphic, energetic lens of New York City, the place TUMI calls home.
The Fall 2025 collections are available at TUMI stores worldwide and on TUMI.com. Stay tuned for exclusive content featuring the Fall 2025 collections on @TUMITravel social channels.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Barnama
2 hours ago
- Barnama
ExP Realty Launches In Japan, Marking Fourth Global Market Entry In 2025
BELLINGHAM, Wash., July 28 (Bernama) -- eXp Realty®, the largest independent real estate brokerage in the world and a core subsidiary of eXp World Holdings, Inc. (Nasdaq: EXPI), today announced its official expansion into Japan, marking the company's fourth international launch of the year, following Peru, Türkiye, and Ecuador. "Agents in Japan have operated for years in a system that leaves little room for upside,' said Felix Bravo, Managing Director, International at eXp Realty. 'It's not about working harder, they already do. The problem is structural. Most models take too much and give too little in return. We're bringing a platform that flips that equation. Better economics, real ownership, worldwide leverage. That's what eXp is about.'
Malaysian Reserve
2 days ago
- Malaysian Reserve
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study of over 600 women from 2006 to 2023 Independent ProSense® study by Professor Hisanori Kawamoto demonstrating 0% breast cancer local recurrence wins Best of Breast Cancer Award Leading US Breast Surgeon, Dr. Richard Fine, presented data from IceCure's ICE3 study & discussed other recent publications on breast cancer cryoablation CAESAREA, Israel, July 25, 2025 /PRNewswire/ — IceCure Medical Ltd. (Nasdaq: ICCM) ('IceCure', 'IceCure Medical' or the 'Company'), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation in the 33rd Annual Meeting of the Japanese Breast Cancer Society's Conference (the 'Conference') which took place earlier this month in Tokyo. 'We believe ProSense® can make a significant impact on improving breast cancer outcomes in Japan by providing women with a minimally invasive option. This year's Conference was highly productive as we engaged with breast surgeons, thought leaders, and industry participants,' stated Eyal Shamir, IceCure's Chief Executive Officer. 'Working with Terumo Corporation in Japan, the country's largest medical device company, we anticipate strong commercial adoption upon regulatory approval for breast cancer, especially given the strong data coming from independent Japanese studies.' IceCure, a sponsor of the Conference, hosted a cryoablation-focused luncheon on Friday, July 11, 2025, led by Professor Takayuki Kinoshita, Division of Breast Surgery, NHO Tokyo Medical Center, with presentations made by: Professor Eisuke Fukuma, who has performed over 600 breast cryoablation procedures, the majority of which were conducted with ProSense®, presented the latest data from his ongoing activity to treat breast cancer at Kameda Medical Center. Professor Fukuma's presentation included the following: From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. Dr. Richard Fine of West Cancer Center & Research Institute in the U.S., and a clinical investigator of IceCure's successfully completed ICE3 breast cancer clinical study, presented findings from the ICE3 study as well as data from independent studies of ProSense® in breast cancer. The Conference gave the Best of Breast Cancer award to an independent study published in the journal Breast Cancer titled 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan'. This study was led by Professor Hisanori Kawamoto, M.D., Ph.D. from the Department of Breast Surgery, Breast and Imaging Center at St. Marianna University School of Medicine in Japan and reported zero (0%) breast cancer local recurrence 5 years following treatment with ProSense®. Dr. Kawamoto commented, 'This is a very important study in Japan, where we are experiencing an upward trend in breast cancer cases, especially among women in their late 40s to their early 60s. These are women who often are at very active stages of their life and therefore there is a growing demand for treatment options that minimize the chance of, or even avoid, hospitalization, in addition to resulting in favorable clinical and cosmetic outcomes. We are very pleased with these results and are hopeful that ProSense® may become a favored option in Japan upon regulatory approval for early-stage breast cancer.' Terumo Corporation is expected to submit an application to the Pharmaceuticals and Medical Devices Agency ('PMDA') of Japan for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. About ProSense®The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver. ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedures for breast tumors. About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the belief that ProSense® can make a significant impact on improving breast cancer outcomes in Japan; the Company's anticipation of strong commercial adoption upon regulatory approval of ProSense® for breast cancer; the belief of the importance of 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan;' and that Terumo Corporation is expected to submit a PMDA application for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. References and links to websites have been provided in this press release as a convenience, and the information contained on such websites is not incorporated by reference herein. IR Contact: Email: investors@ Michael Polyviou Phone: 732-232-6914 Logo – View original content:
Malaysian Reserve
2 days ago
- Malaysian Reserve
Jones Walker Welcomes State and Local Tax Attorney Kyle Brehm and Expands Into Minnesota
MINNEAPOLIS, July 25, 2025 /PRNewswire/ — Jones Walker LLP is pleased to welcome Kyle Brehm as a partner in the Tax Practice Group and a member of the firm's state and local tax team based in Minneapolis. Kyle's addition to the firm expands the firm's reach into the Minnesota market. 'We are pleased to welcome Kyle to Jones Walker,' said Bill Hines, the firm's managing partner. 'His extensive experience in state and local tax law, as well as indirect tax issues, expands the reach of our robust tax practice into Minnesota and strengthens the value we provide to clients nationwide.' Kyle is a state and local tax (SALT) attorney with nearly two decades of experience providing strategic value to clients across a broad range of industries. He draws on his extensive background at a Big Four accounting firm and in private legal practice to deliver sophisticated counsel on the full spectrum of SALT matters, from compliance and planning to dispute resolution and transactional support. Kyle also has particular experience in multistate indirect tax issues, including complex post-Wayfair sales and use tax matters. 'I've been watching Jones Walker build one of the preeminent teams of state and local tax attorneys over the last several years,' Kyle said, 'and could not be more thrilled or more proud to join this group of colleagues.' Kyle represents clients in connection with state tax compliance strategies, audit defense, and dispute resolution. With an emphasis on building close, long-lasting working relationships, he works with executives and in-house tax and legal departments to identify tax savings and leverage opportunities related to existing, revised, and proposed state and federal legislation and administrative rulings. Kyle also provides strategic counsel on the state and local tax implications of a wide range of business transactions, including entity restructuring, mergers, and acquisitions, and conducts related due diligence. About Jones WalkerJones Walker LLP ( is among the largest 145 law firms in the United States. With offices in Alabama, Arizona, the District of Columbia, Florida, Georgia, Kentucky, Louisiana, Minnesota, Mississippi, New York, and Texas, we serve local, regional, national, and international business interests. The firm is committed to providing a comprehensive range of legal services to major multinational public and private corporations, Fortune® 500 companies, money center banks, worldwide insurers, and emerging companies doing business in the United States and abroad. Contact: Savannah Kirk225.248.3435skirk@
